Irritable Bowel Syndrome (IBS) Market Report

Global Irritable Bowel Syndrome (IBS) Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 02, 2022
  • PAGES：196
  • REPORT CODE：GMM792792
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Irritable Bowel Syndrome (IBS) market report explains the definition, types, applications, major countries, and major players of the Irritable Bowel Syndrome (IBS) market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Valeant Pharmaceuticals

    • Allergan

    • Takeda

    • McNeil Consumer Healthcare

    • Sucampo Pharmaceuticals

    • IM HealthScience

    • Astellas Pharmaceuticals

    • Sebela Pharmaceuticals

    By Type:

    • IBS-D Drug

    • IBS-C Drug

    • Other

    By End-User:

    • Other

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Irritable Bowel Syndrome (IBS) Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Irritable Bowel Syndrome (IBS) Outlook to 2028- Original Forecasts

    • 2.2 Irritable Bowel Syndrome (IBS) Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Irritable Bowel Syndrome (IBS) Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Irritable Bowel Syndrome (IBS) Market- Recent Developments

    • 6.1 Irritable Bowel Syndrome (IBS) Market News and Developments

    • 6.2 Irritable Bowel Syndrome (IBS) Market Deals Landscape

    7 Irritable Bowel Syndrome (IBS) Raw Materials and Cost Structure Analysis

    • 7.1 Irritable Bowel Syndrome (IBS) Key Raw Materials

    • 7.2 Irritable Bowel Syndrome (IBS) Price Trend of Key Raw Materials

    • 7.3 Irritable Bowel Syndrome (IBS) Key Suppliers of Raw Materials

    • 7.4 Irritable Bowel Syndrome (IBS) Market Concentration Rate of Raw Materials

    • 7.5 Irritable Bowel Syndrome (IBS) Cost Structure Analysis

      • 7.5.1 Irritable Bowel Syndrome (IBS) Raw Materials Analysis

      • 7.5.2 Irritable Bowel Syndrome (IBS) Labor Cost Analysis

      • 7.5.3 Irritable Bowel Syndrome (IBS) Manufacturing Expenses Analysis

    8 Global Irritable Bowel Syndrome (IBS) Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Irritable Bowel Syndrome (IBS) Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Irritable Bowel Syndrome (IBS) Export by Region (Top 10 Countries) (2017-2028)

    9 Global Irritable Bowel Syndrome (IBS) Market Outlook by Types and Applications to 2022

    • 9.1 Global Irritable Bowel Syndrome (IBS) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global IBS-D Drug Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global IBS-C Drug Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Other Consumption and Growth Rate (2017-2022)

    • 9.2 Global Irritable Bowel Syndrome (IBS) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Other Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Irritable Bowel Syndrome (IBS) Market Analysis and Outlook till 2022

    • 10.1 Global Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.2.2 Canada Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.2.3 Mexico Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.2 UK Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.3 Spain Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.4 Belgium Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.5 France Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.6 Italy Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.7 Denmark Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.8 Finland Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.9 Norway Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.10 Sweden Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.11 Poland Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.12 Russia Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.3.13 Turkey Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.2 Japan Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.3 India Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.4 South Korea Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.5 Pakistan Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.6 Bangladesh Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.7 Indonesia Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.8 Thailand Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.9 Singapore Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.10 Malaysia Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.11 Philippines Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.4.12 Vietnam Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.5.2 Colombia Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.5.3 Chile Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.5.4 Argentina Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.5.5 Venezuela Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.5.6 Peru Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.5.7 Puerto Rico Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.5.8 Ecuador Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.6.2 Kuwait Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.6.3 Oman Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.6.4 Qatar Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.7.2 South Africa Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.7.3 Egypt Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.7.4 Algeria Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

      • 10.8.2 New Zealand Irritable Bowel Syndrome (IBS) Consumption (2017-2022)

    11 Global Irritable Bowel Syndrome (IBS) Competitive Analysis

    • 11.1 Valeant Pharmaceuticals

      • 11.1.1 Valeant Pharmaceuticals Company Details

      • 11.1.2 Valeant Pharmaceuticals Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Valeant Pharmaceuticals Irritable Bowel Syndrome (IBS) Main Business and Markets Served

      • 11.1.4 Valeant Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Allergan

      • 11.2.1 Allergan Company Details

      • 11.2.2 Allergan Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Allergan Irritable Bowel Syndrome (IBS) Main Business and Markets Served

      • 11.2.4 Allergan Irritable Bowel Syndrome (IBS) Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Takeda

      • 11.3.1 Takeda Company Details

      • 11.3.2 Takeda Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Takeda Irritable Bowel Syndrome (IBS) Main Business and Markets Served

      • 11.3.4 Takeda Irritable Bowel Syndrome (IBS) Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 McNeil Consumer Healthcare

      • 11.4.1 McNeil Consumer Healthcare Company Details

      • 11.4.2 McNeil Consumer Healthcare Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 McNeil Consumer Healthcare Irritable Bowel Syndrome (IBS) Main Business and Markets Served

      • 11.4.4 McNeil Consumer Healthcare Irritable Bowel Syndrome (IBS) Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Sucampo Pharmaceuticals

      • 11.5.1 Sucampo Pharmaceuticals Company Details

      • 11.5.2 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Main Business and Markets Served

      • 11.5.4 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 IM HealthScience

      • 11.6.1 IM HealthScience Company Details

      • 11.6.2 IM HealthScience Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 IM HealthScience Irritable Bowel Syndrome (IBS) Main Business and Markets Served

      • 11.6.4 IM HealthScience Irritable Bowel Syndrome (IBS) Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Astellas Pharmaceuticals

      • 11.7.1 Astellas Pharmaceuticals Company Details

      • 11.7.2 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Main Business and Markets Served

      • 11.7.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Sebela Pharmaceuticals

      • 11.8.1 Sebela Pharmaceuticals Company Details

      • 11.8.2 Sebela Pharmaceuticals Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Sebela Pharmaceuticals Irritable Bowel Syndrome (IBS) Main Business and Markets Served

      • 11.8.4 Sebela Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    12 Global Irritable Bowel Syndrome (IBS) Market Outlook by Types and Applications to 2028

    • 12.1 Global Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global IBS-D Drug Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Other Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Irritable Bowel Syndrome (IBS) Market Analysis and Outlook to 2028

    • 13.1 Global Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.2.2 Canada Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.2 UK Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.3 Spain Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.5 France Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.6 Italy Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.8 Finland Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.9 Norway Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.11 Poland Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.12 Russia Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.2 Japan Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.3 India Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.5.3 Chile Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.5.6 Peru Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.6.3 Oman Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Irritable Bowel Syndrome (IBS) Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Irritable Bowel Syndrome (IBS)

    • Figure of Irritable Bowel Syndrome (IBS) Picture

    • Table Global Irritable Bowel Syndrome (IBS) Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Irritable Bowel Syndrome (IBS) Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global IBS-D Drug Consumption and Growth Rate (2017-2022)

    • Figure Global IBS-C Drug Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Irritable Bowel Syndrome (IBS) Consumption by Country (2017-2022)

    • Table North America Irritable Bowel Syndrome (IBS) Consumption by Country (2017-2022)

    • Figure United States Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Canada Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Mexico Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Table Europe Irritable Bowel Syndrome (IBS) Consumption by Country (2017-2022)

    • Figure Germany Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure UK Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Spain Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Belgium Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure France Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Italy Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Denmark Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Finland Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Norway Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Sweden Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Poland Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Russia Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Turkey Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Table APAC Irritable Bowel Syndrome (IBS) Consumption by Country (2017-2022)

    • Figure China Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Japan Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure India Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Thailand Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Singapore Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Philippines Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Table South America Irritable Bowel Syndrome (IBS) Consumption by Country (2017-2022)

    • Figure Brazil Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Colombia Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Chile Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Argentina Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Peru Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Table GCC Irritable Bowel Syndrome (IBS) Consumption by Country (2017-2022)

    • Figure Bahrain Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Oman Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Qatar Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Table Africa Irritable Bowel Syndrome (IBS) Consumption by Country (2017-2022)

    • Figure Nigeria Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure South Africa Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Egypt Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure Algeria Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Table Oceania Irritable Bowel Syndrome (IBS) Consumption by Country (2017-2022)

    • Figure Australia Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Irritable Bowel Syndrome (IBS) Consumption and Growth Rate (2017-2022)

    • Table Valeant Pharmaceuticals Company Details

    • Table Valeant Pharmaceuticals Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Valeant Pharmaceuticals Irritable Bowel Syndrome (IBS) Main Business and Markets Served

    • Table Valeant Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio

    • Table Allergan Company Details

    • Table Allergan Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Irritable Bowel Syndrome (IBS) Main Business and Markets Served

    • Table Allergan Irritable Bowel Syndrome (IBS) Product Portfolio

    • Table Takeda Company Details

    • Table Takeda Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Takeda Irritable Bowel Syndrome (IBS) Main Business and Markets Served

    • Table Takeda Irritable Bowel Syndrome (IBS) Product Portfolio

    • Table McNeil Consumer Healthcare Company Details

    • Table McNeil Consumer Healthcare Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table McNeil Consumer Healthcare Irritable Bowel Syndrome (IBS) Main Business and Markets Served

    • Table McNeil Consumer Healthcare Irritable Bowel Syndrome (IBS) Product Portfolio

    • Table Sucampo Pharmaceuticals Company Details

    • Table Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Main Business and Markets Served

    • Table Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio

    • Table IM HealthScience Company Details

    • Table IM HealthScience Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table IM HealthScience Irritable Bowel Syndrome (IBS) Main Business and Markets Served

    • Table IM HealthScience Irritable Bowel Syndrome (IBS) Product Portfolio

    • Table Astellas Pharmaceuticals Company Details

    • Table Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Main Business and Markets Served

    • Table Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio

    • Table Sebela Pharmaceuticals Company Details

    • Table Sebela Pharmaceuticals Irritable Bowel Syndrome (IBS) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sebela Pharmaceuticals Irritable Bowel Syndrome (IBS) Main Business and Markets Served

    • Table Sebela Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio

    • Figure Global IBS-D Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global IBS-C Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Irritable Bowel Syndrome (IBS) Consumption Forecast by Country (2022-2028)

    • Table North America Irritable Bowel Syndrome (IBS) Consumption Forecast by Country (2022-2028)

    • Figure United States Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Irritable Bowel Syndrome (IBS) Consumption Forecast by Country (2022-2028)

    • Figure Germany Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Irritable Bowel Syndrome (IBS) Consumption Forecast by Country (2022-2028)

    • Figure China Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Irritable Bowel Syndrome (IBS) Consumption Forecast by Country (2022-2028)

    • Figure Brazil Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Irritable Bowel Syndrome (IBS) Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Irritable Bowel Syndrome (IBS) Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Irritable Bowel Syndrome (IBS) Consumption Forecast by Country (2022-2028)

    • Figure Australia Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Irritable Bowel Syndrome (IBS) Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US